SUPERNUS PHARMACEUTICALS, INC.
Loading stock data...
Key Financial Metrics (TTM | FY 2025)
$718.95M
Revenue
$-38.55M
Net Income
-0.68
EPS (Diluted)
$164.62M
Free Cash Flow
Profitability
Gross Margin
89.63%
Operating Margin
-8.66%
Net Profit Margin
-5.36%
EBITDA
$91.40M
Returns & Efficiency
Return on Assets (ROA)
-2.65%
Return on Equity (ROE)
-3.63%
Gross Profit
$644.39M
Operating Income
$-62.28M
Financial Health
Total Assets
$1.45B
Total Debt
-
Debt to Equity
0.37x
Current Ratio
1.90
Debt Analysis
Debt to EBITDA
-
Debt to Free Cash Flow
-
Cash & Equivalents
-
Net Debt
-
Capital Returns
Return on Invested Capital (ROIC)
-
Invested Capital
-
Stockholders Equity
-
Revenue Growth
-
Market Valuation
Market Cap
-
P/E Ratio
-
Price to Book
-
EPS (Diluted)
$-0.68
Quick Access Filings
10-K
Annual Report
Loading...
10-Q
Quarterly Report
Loading...
8-K
Recent News
Loading...
Company Data Library
Earnings Transcripts
Loading...
Press Releases
Loading...
Filing Sections
Loading...
Financial Charts Annual (10-K)
Interactive financial visualizations
Show:
Revenue & Income Trends
Revenue & Profit
Profit Margins
Balance Sheet Breakdown
Assets Composition
Capital Structure
Cash Flow Analysis
Cash Flow Components
Free Cash Flow
Growth & Performance
Revenue Growth Rate (YoY %)
Key Ratio Trends
Insider Transactions
Neutral
Open Market Buys: -
Open Market Sales: -
Option Exercise & Sale: -
Net: -
Loading...
Loading insider transactions...
My Notes & Files
Personal Notes
Attached Files
Loading...
SEC Filings by Category
Insider Trading Activity
Neutral
0 Buys $0
0 Sales $0
0 Exercises $0
Net: $0
| Insider | Title | Date | Type | Shares | Price | Value |
|---|
Company Information
| Business Address |
9715 KEY WEST AVENUE
ROCKVILLE, MD 20850 |
| Phone | 301-838-2500 |
| Incorporated | DE, US |
| EIN | 000000000 |
| Fiscal Year End | 1231 |
| Stockholders' Equity | $1.06B |
| Cash & Equivalents | $128.45M |
Recent Filings
View All
4
Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-03-18
Local
144
Proposed Sale Notice
Notice of proposed sale of securities
Filed: 2026-03-17
Local
144
Proposed Sale Notice
Notice of proposed sale of securities
Filed: 2026-03-16
Local
4
Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-03-16
Local
4
Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-03-16
Local
144
Proposed Sale Notice
Notice of proposed sale of securities
Filed: 2026-03-10
Local
4
Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-03-10
Local
4
Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-03-10
Local
4
Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-03-10
Local
4
Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-03-10
Local
3
Initial Ownership Report
Initial statement of beneficial ownership of securities
Filed: 2026-03-10
Local
144
Proposed Sale Notice
Notice of proposed sale of securities
Filed: 2026-03-09
Local
144
Proposed Sale Notice
Notice of proposed sale of securities
Filed: 2026-03-09
Local
4
Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-03-09
Local
144
Proposed Sale Notice
Notice of proposed sale of securities
Filed: 2026-03-05
Local
Financial Statistics
Valuation
Market Cap
-
P/E Ratio (TTM)
-
Price to Book
-
EV/Revenue
-
EV/EBITDA
-
Profitability
Gross Margin
89.6%
Operating Margin
-8.7%
Net Margin
-5.4%
ROE
-3.6%
ROA
-2.7%
Leverage & Liquidity
Debt to Equity
0.37
Current Ratio
1.90
Total Debt
-
Total Assets
$1.45B
Stockholders' Equity
$1.06B
Income Statement (FY 2025)
Revenue
$718.95M
Gross Profit
$644.39M
Operating Income
$-62.28M
Net Income
$-38.55M
EPS (Diluted)
$-0.68
Cash Flow (FY 2025)
Free Cash Flow
$164.62M
Cash & Equivalents
$128.45M
Revenue Growth
8.6%
Loading...
Loading management data...
Loading...
Loading board of directors...
Loading...
Loading institutional holders...